Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05366439 · ClinicalTrials.gov registry record · Phase 1
Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model
A Phase 1 study, sponsored by Atea Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT05366439: Clinical Trial Phase 1 study, sponsored by Atea Pharmaceuticals.
NCT05366439 is a Phase 1 study that was terminated before completion, run by Atea Pharmaceuticals. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05366439, a Phase 1 study, was terminated before completion, sponsored by Atea Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study will assess the safety and antiviral activity of AT-752 in healthy subjects in a Dengue Human Challenge Model
Interventions
- DRUG Placebo Comparator
- DRUG AT-752
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2023-03-16 |
| Phase | Phase 1 |
Why NCT05366439 stopped before completion
NCT05366439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT05366439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05366439 about?
NCT05366439 is a clinical study titled "Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model". This study will assess the safety and antiviral activity of AT-752 in healthy subjects in a Dengue Human Challenge Model
What is the current status of trial NCT05366439?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2022-04-22. Estimated completion is 2023-03-16.
What interventions are being tested in trial NCT05366439?
The interventions under investigation include: Placebo Comparator (DRUG), AT-752 (DRUG).
Who is sponsoring clinical trial NCT05366439?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05366439's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI